Phase I evaluation of continuous 5-fluorouracil infusion followed by weekly paclitaxel in patients with advanced or recurrent gastric cancer

Japanese Journal of Clinical Oncology

Volumn 35, Issue 6, 2005, Pages 332-337

  Kondo, Ken ^a   Kobayashi, Michiya ^b   Kojima, Hiroshi ^c   Hirabayashi, Naoki ^d   Kataoka, Masato ^a   Araki, Kyoujiro ^b   Matsui, Takanori ^c   Takiyama, Wataru ^d   Miyashita, Yumi ^c   Nakazato, Hiroaki ^e   Nakao, Akimasa ^f   Sakamoto, Junichi ^g  

^a NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^b KOCHI MEDICAL SCHOOL   (Japan)

^c AICHI PREFECTURAL UNIVERSITY   (Japan)

^d HIROSHIMA CITY ASA HOSPITAL   (Japan)

^e Japanese Foundation for Multidisciplinary Treatment of Cancer   (Japan)

^f NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Gastric cancer; Weekly paclitaxel

Indexed keywords

FLUOROURACIL; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG MECHANISM; DRUG METABOLISM; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; HYPONATREMIA; LIVER DYSFUNCTION; MALE; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; RECURRENT CANCER; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; FEASIBILITY STUDY; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; MORTALITY; STOMACH TUMOR; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FLUOROURACIL; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEUTROPENIA; PACLITAXEL; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 23844543459     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyi096     Document Type: Article

References (24)

1. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke A, et al. Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-7.
2. Moertel CG, Rubin J, O'Connell MJ, Schutt AJ, Wieand HS. A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinoma. J Clin Oncol 1986;4:1053-7.
3. Ohtsu A, Shimada Y, Yoshida S, Saito H, Seki S, Morise K, et al. Phase II study of protracted infusional 5-fluorouracil combined with cisplatinum for advanced gastric cancer: Report from the Japan Clinical Oncology Group (JCOG). Eur J Cancer 1994;14:2091-3.
4. Koizumi W, Kurihara M, Nakano S, Hasegawa K. Phase I study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group. Oncology 2000;58:191-7.
5. Bugat R. Irinotecan in the treatment of gastric cancer. Ann Oncol 2003;14:37-40.
6. Roth AD. Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 2003;14:41-4.
7. Jacob J, Lokich J, Ahlgren JD, Gullo JJ, Philips A, Fryer AGJ. Prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carconoma: A Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;4:425-32.
8. Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, et al. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions. Ann Oncol 2001;12:1133-7.
9. Fennelly D, Aghajanian C, Shapiro F, O'Flaherty C, McKenzie M, O'Connor C, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92.
10. Klaassen U, Wilke H, Strumberg D, Eberhardt W, Korn M, Seeber S. Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 1996;32A:547-9.
11. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL Jr, et al. Phase I trial of intraperitoneal taxol: A Gynecologic Oncology Group Study. J Clin Oncol 1992;10:1485-91.
12. Kano Y, Akutsu M, Tsunoda S, Matsui J, Suzuki K, Ikeda T, et al. Schedule-dependent interaction between paclitaxel and 5-fluorouracil in human carcinoma cell lines in vitro. Br J Cancer 1996;74:704-10.
13. National Cancer Institute. NCI common toxicity criteria, version 1. In Investigators Handbook: A Manual of Participants in Clinical Trials of Investigational Agents Sponsored by the Division of Cancer Treatment, National Cancer Institute. Bethesda, MD, US. Department of Health and Human Services, Public Health Service, National Institute of Health, October 1993.
14. Ajani JA, Van Cutsem E, Moiseyenko V, Tjulandin S, Fodor M, Majlis A, et al. Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC). Interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 2003;249:999 (abstr).
15. Chang YF, Li LL, Wu CW, Liu TY, Peng FK, Chi CW. Paclitaxel-induced apotosis in human gastric cell lines. Cancer 1996;77:14-8.
16. Yamaguchi K, Tada M, Horikoshi N, Otani T, Takiuchi H, Saitoh S, et al. Phase II study of paclitaxel with 3-h infusion in patients with advanced gastric cancer. Gastric Cancer 2002;5:90-5.
17. Cascinu S, Ficarelli R, Safi MAA, Greziano FA, Catalano G, Cellerino R. A phase I study of paclitaxel and 5-fluorouracil in advanced gastric cancer. Eur J Cancer 1997;33:1699-702.
18. Bokemeyer C, Hartmann JT, Lampe CS, Clemens MR, Quietzsch D, Forkman L, et al. Paclitaxel and weekly 24-hour infusion of 5-fluorouracil/folinic acid in advanced gastric cancer. Semin Oncol 1997;24 (Suppl 19):96-100.
19. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G, Piedbois P. Relation between tumour respones to first-line chemotherapy and survival in advanced colorectal cancer: A meta-anaiysis. Meta-Analysis Group in Cancer. Lancet 2000;356:373-8.
20. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyoudo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 2003;21:54-9.
21. Sakamoto J. A new paradigm of chemotherapy for gastric cancer: Speeding up, and more clinical trials to catch up. Gastric Cancer 2002;5:55-7.
22. Eisenhauer EA, Huinink WW, Swenerton KD. European Canadian randomized trial of paclitaxel in relapsed ovarian cancer. High-dose versus low-dose, and long versus short infusion. J Clin Oncol 1994;12:2654-66.
23. Seidman AD, Hudis CA, Albanel J, Tong W, Tepler I, Currie V, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Oncol 1998;16:3353-61.
24. Tamura T, Sasaki Y, Nishiwaki Y, Saijo N. Phase I study of paclitaxel by three-hour infusion: Hypotension just after infusion is one of the major dose-limiting toxicites. Jpn J Cancer Res 1995;86:1203-9.